Abstract: Most of the floating systems have an inherent drawback of high variability in the GI transit time, invariably affecting the bioavailability of drug. An attempt has been made to develop floating drug delivery system for improving the drug bioavailability by prolongation of gastric residence time of famotidine in stomach. The floating microballoons were prepared using polymer Eudragit L-100 by solvent evaporation and diffusion technique. The prepared famotidine loaded microspheres were characterised for drug loading, entrapment, encapsulation efficiency, particle size distribution, surface morphology, differential scanning calorimetry, test for buoyancy, in-vitro release and in-vivo antiulcer studies. The results showed an increased drug loading, encapsulation and entrapment efficiency. The thermogram of the DSC showed that the drug was encapsulated in amorphous form and SEM studies revealed the discrete, spherical shaped spheres with rough surface and presence of holes on floating microspheres due high entrapment of PEG which are responsible for drug release and floating ability. The sizes of spheres were found between 20-120 m which exhibited prolonged release (Invitro > 8 h) and remained buoyant for > 10 h. The mean particle size increased and the drug release rate decreased at higher Eudragit L-100 polymer concentration. The in-vivo results showed significant antiulcer property of famotidine loaded microspheres when compared to control and standard group of rats by using pyloric ligation method. The mean volume of gastric secretion, mean pH and mean total acid for formulation treated group was calculated as 3.45+0.88 ml, 5.65+ 0.74, and 114.15+1.80 mEq/L respectively.
INTRODUCTION
Oral drug delivery systems should be primarily aimed at achieving more predictable and increased bioavailability of the drugs and it is necessary to optimize both the residence time of the system within the gastrointestinal tract and the release rate of the drug from the system. However, the development process is precluded by several physiological difficulties, such as inability to restrain and localize the drug delivery system within desired regions of the gastrointestinal tract (GIT) and the highly variable nature of gastric emptying process. Various attempts have been made to prolong the residence time of the dosage forms within the stomach [1, 2] . The prolongation of the gastric residence time (GRT) of delivery system could be achieved by design of pharmaceutical formulation which depends on the physiological state of the stomach and maintaining them in buoyant fashion in gastric juice [3] [4] [5] . One such approach is the floating dosage forms [6] . They have low density as compared to that of gastric fluids, due to which they float in the stomach contents for a longer period of time. But most of the floating systems have an inherent drawback of high variability in the GI transit time invariably affecting the bioavailability of drug. Thus, in a view to explore a system with extended GI transit time capable of distributing widely throughout the GIT for effective enteric release of drug has been sought. Recently, El-*Address correspondence to this author at the Research Lab., GIET School of Pharmacy, NH-5, Chaitanya Nagar, Rajahmundry-533 294, India; Tel: +918832484444, 6577444; Fax: +918832484739, 2484444; Mobile: +919440677600; E-mail: mddhanaraju@yahoo.com Kamel et al. [7] described a floating multiple-unit system for ketoprofen employing Eudragit S100 alone or a mixture with the permeable Eudragit RL. Kawashima et al. [8] developed hollow microspheres (microballoons) to prolong GRT of the dosage form.
Famotidine is a histamine H2-receptor antagonist. It is widely prescribed in gastric ulcers, duodenal ulcers, Zollinger-Ellison syndrome and gastro oesophageal reflux disease. In this study, hollow microspheres (microballoons) of famotidine developed by a novel emulsion-solvent evaporation technique for sustained delivery by using non-toxic polymer Eudragit L-100. Microspherees were evaluated for its loading, entrapment, encapsulation, particle size distribution, surface morphology, test for buoyancy, in-vitro release and in-vivo antiulcer studies.
MATERIALS AND METHODS
Famotidine was obtained as a gift sample from Aristo Pharmaceuticals, Mumbai. Eudragit L-100 was purchased from Rohm GMBH, Germany. All other reagents were of analytical grade and were used as received.
Preparation of Microspheres
Polymer solution was prepared by dissolving Eudragit L-100 and PEG 6000(10%) in acetone ethanol mixture (30:70). Weighed amount of famotidine was mixed with the polymer solution at the ratios of 1:1, 1:2 and 1:5 at room temperature. The drug-polymer solution was transferred in liquid paraffin and propelled at 400 rpm for 10 min and placed in magnetic stirrer for 2 h at 300 rpm at 37°C. Microspheres formed were separated from liquid paraffin using petroleum ether, the resultant microspheres were filtered by using nylon cloth, washed repeatedly with distilled water and dried under vacuum.
Characterization of Famotidine Loaded Microspheres

Determination of Famotidine Loading Efficiency
The famotidine loaded microspheres can be estimated by the equation
Where L = percentage loading of microspheres, W m = weight of microspheres in grams, Q M = quantity of famotidine present in W m gram of microspheres.
Determination of Encapsulation Efficacy of Microspheres
The amount of famotidine encapsulated was determined by taking a known weight of microspheres into screwcapped vials with 0.1 N HCl and digested for 24 hours on a magnetic stirrer in order to extract the entrapped drug completely. After suitable dilution absorbance was measured at 265 nm by using UV-Spectrophotometer (ELICO-SL151). Blank microspheres treated in a similar manner were used as the blank [10] . The amount of famotidine encapsulated in the microspheres was determined by
Where E = the percentage encapsulated microspheres, Q p = Quantity of drug encapsulated in microspheres, Q t = Quantity of drug added for encapsulation
Scanning Electron Microscopy
The sample of the SEM analysis was prepared by sprinkling the microsphere onto one side of the double adhesive stub. The stubs were then coated with gold using polaran SC 500 sputter coater, to neutralize the electrons and to obtain a clear morphology of the spheres. The optical micrographs were also taken using Leica storeoscan 440, Leica Cambridge limited, U.K. The SEM was performed on microspheres after and before dispersing it in 0.1N HCl.
Particle Size Determination
The microspheres were dispersed in water, the size of the microspheres were determined by using calibrated eye piece micrometer. The particle size distribution was plotted and the average size was determined.
Differential Scanning Calorimetry
Differential scanning calorimetry was performed for famotidine , Eudragit L-100 , PEG6000 and drug loaded microspheres using PERKIN ELMER OSC-7 model calibrated with indium.
Test for Buoyancy
The floating time was determined by dispersing 100 mg of microspheres in 500 ml beaker containing 400ml of 0.1N HCl at 37 o C under stimulated gastric fluid with paddle rotation of 100 rpm. Each fraction of microspheres floating on the surface and those settled down were collected at a predetermined time intervals [10] .
% floating microspheres= (weight of floating microspheres/ initial weight of floating microspheres) 100.
In-Vitro Release Studies
The in-vitro release studies of drug loaded microspheres were carried out at 37 o C using pH 4.5 phosphate buffer. Each batch of microsphere equivalent to 100 mg of famotidine was individually added to 250 ml of medium in an iodine flask and shaken at 50 rpm in an incubator at 37 o C. The samples were withdrawn at regular intervals from the dissolution medium and analyzed at 265 nm by using UVSpectrophotometer (ELICO-SL151). Equal volume of the dissolution medium was replaced in the vessel after each withdrawal to maintain sink condition.
In-Vivo Antiulcer Studies by Pyloric Ligation Method
Wistar albino rats of either sex were grouped into 3, each containing 6 animals, they were kept in the animal house at room temperature 25±2 o C, with relative humidity of 45-55%, maintained under 12 hrs light and dark cycle and were fed with standard animal feed and were acclimatized for a week before the study. Group I served as disease control in which distilled water was administered orally, group II received famotidine-2.5 mg/kg orally and it was considered as standard, group III received microsphere formulation equivalent to 2.5 mg/kg of the famotidine orally which served as test.
Pyloric ligation method was performed as described by Shay et al. [11, 12] . Rats were fasted for 36 hours prior to the surgical procedure and kept in raised mesh -bottomed cages to avoid coprophagy. Under ether anesthesia the abdomen was opened by a small mid line incision below the xiphoid process. The pyloric portion of the stomach was identified, slightly lifted, avoiding traction to the pylorus or damage to the blood supply. After exposing the stomach, pass a thread around the pyloric sphincter and apply a tight knot. The stomach was then replaced carefully and the abdominal wall closed by interrupted sutures. Animals were deprived of both food and water during the post operative period and were sacrificed at the end of 19-20 hours after the operation. The stomach was dissected out as a whole by passing a ligature at the esophageal end.
The stomach was separated from the surrounding tissues and organs and thus brought out as a whole along with its contents. The contents were subjected to centrifugation (3000 rpm for 10 min) and then analyzed for mean volume of gastric secretion, mean pH and mean total acid. The pH was estimated using indikrom pH strips (Glaxo India limited, India) with pH ranges of 2.0 -4.5 and 5.0 -8.5 with a difference in range of 0.5. Free acidity and total acidity were estimated by titrating 1 ml of centrifuged sample with 0.01N NaOH, using Topfer's reagent as indicator and phenolphthalein indicator, respectively. Acidity was expressed in clinical units that are the amount of 0.01N NaOH base required to titrate 100 ml of gastric secretion.
This study was conducted in accordance with the guidelines given by "Institutional Animal Ethics Committee" (IAEC) approval number-GSP/PY/08/2008.
RESULTS AND DISCUSSION
Floating microspheres were prepared by using simple solvent evaporation method by using Eudragit L-100 as a polymer and PEG 6000 a pore former in Eudragit L-100 microspheres to enhance the floating property. The good buoyancy behavior of the microspheres may be attributed to the hollow nature of the microspheres due to pore former PEG 6000. When the microspheres were dispersed in water pores were formed due to high water solubility of PEG, this made the spheres to swell and float on the stimulated gastric fluid. Drug loading in Eudragit L-100 microspheres was found to be 5 -26% w/w depending on drug-polymer ratio. The percentage of entrapment was found to be between 33 -56% w/w and the efficiency of encapsulation was found to be 24.4-43.6% w/w as shown in Table 1 . Fig. (1) The SEM photograph showed that microspheres were found to be discrete, free flowing and spherical in shape with rough surface and it exhibited a range of sizes. The photograph of floating microsphere showing pores on the surface which is responsible for release and floating. The microspheres floated for prolonged time (>10 h) over the surface of the dissolution medium without any apparent gelation [10] .
Microspheres were prepared by increasing the concentration of Eudragit L-100 polymer. The mean particle size of the microsphere significantly increased with the increase in Eudragit L-100 polymer concentration and was ranged from 20 -120 m as shown in Fig. (2) . DSC thermogram of famotidine, Eudragit L-100, PEG 6000 and floating microspheres were made in an attempt to define the physical state of drug and possibility of interaction between drug and the polymer. The results are depicted in Fig. (3) . The thermogram of famotidine showed an endothermic peak at 163.33 o C, which corresponds to the melting point of famotidine (160-163 o C). The thermogram of Eudragit L-100 and PEG 6000 were identical with an endothermic peak at 205 o C and PEG 6000 showed a peak at 62.337 o C which were identical with an endothermic peak at 204 o C and 63 o C corresponding to melting temperature of carriers respectively. Results indicated that there was no shift in the level of peak of drug and polymer, at the same time the microspheres did not show endothermic peak of drug, implying that the drug was present in the molecular level at polymer melting temperature. It could be concluded that Eudragit L-100 maintained its characteristic in the floating microspheres prepared.
Fig. (1).
Scanning electron microphotographs of Eudragit L-100 microspheres.
Fig. (2).
Particle size distribution of Eudragit L-100 microspheres.
To assess the floating property, the microsphere were placed in pH 4.5 phosphate buffer containing surface acting agent Tween 20 to stimulate in-vivo condition of phosphol- ipid in GIT. The buoyancy percentage of microsphere was in the range 57-64.4% at the end of 12 h. When the microspheres were dispersed in water pores were formed due to high water solubility of PEG, this made the spheres to swell and float [9] . The in-vitro release studies results are shown in Fig. (4) . The initial release of famotidine floating microsphere was high which was due to the presence of higher amount of PEG in microspheres that resulted in faster release of drug. The presence of pores in floating microsphere was responsible for faster dissolution rate. A cumulative release of famotidine significantly decreased with increasing the Eudragit L-100 polymer concentration. The increased density of the polymer matrix at higher concentration results in an increased diffusional path length. This may decrease the over all drug release from polymer matrix. Furthermore, microspheres are formed at lower polymer concentration and have a large surface area exposed to dissolution medium giving rise to faster drug release.
The in-vivo antiulcers study was carried out by using pyloric ligation method in rats. From the results of Table 2 it is evident that the microsphere formulation has reduced the mean volume of gastric secretion at the dose level equivalent to 2.5 mg/kg of famotidine when compared to control group. Standard group that received famotidine also showed significant reduction in mean volume of gastric secretion. At the same time pH of the gastric juice was also increased for formulation administered animals. Total acidity was also comparatively reduced with that of the control. From Figs. (5-7) it can be assumed that the ulcer spots produced in control group of animals was found to be more when compared to the ulceration produced in standard group and microsphere administered groups. From the above factors it is proved that the formulated microspheres exhibited significant antiulcer property equal to that of standard famotidine.
CONCLUSION
Floating hollow microspheres of famotidine were prepared by solvent evaporation-diffusion method which showed significant floating ability, good buoyancy and prolonged drug release. SEM results proved that rough surfaced spherical hollow microspheres with holes which enhance the floating time and DSC results showed the thermogram of famotidine which was encapsulated in amorphous form. Invitro release study indicated that Famotidine was released in controlled manner upto 8 hours proving that Eudragit L -100 microspheres were potential candidate to prolong the residence time in stomach and to enhance the bioavailability of drug.
In-vivo antiulcer study showed significant antiulcer property by using pyloric ligation method in rats, it is evident that the microsphere formulation showed effect equivalent to standard drug famotidine by projecting it as successful formulation. Fig. (6) . Inner stomach wall of animal treated with standard famotidine.
Fig. (7)
. Inner stomach wall of animal treated with microsphere formulation.
